Just as genetic diversity varies, the metabolic characteristics of cancer exhibit significant heterogeneity due to varied signals within the tumor microenvironment. Hence, addressing metabolic adaptability is crucial when developing cancer immunotherapy strategies.

Utilizing our proprietary Mass Spectrometry Imaging and GeoMx platforms, we were able to evaluate the interactions between metabolic pathways and functions of immune cells to assist in the development of new cancer metabolism drugs. A combined workflow of Quantitative Mass Spectrometry Imaging (QMSI) and GeoMx allows for a better understanding of both direct and indirect modulation of anti-tumor immunity through a better understanding of the tumor immune cell interface.

Download our application note to learn more:

Download Now